Use of epidermal growth factor receptor (EGF-R) antagonist for the manufacture of a medicament for the treatment of hypersecretion of mucus in airways

摘要

Use of an epidermal growth factor receptor (EGF-R) antagonist for the manufacture of a medicament for the treatment of hypersecretion of mucus in airways related with pulmonary disease chosen from chronic obstructive pulmonary disease, chronic bronchitis, acute asthma, cystic fibrosis and bronchiectasis, wherein EGF-R antagonist reduces hypersecretion of mucus in airways and being tyrosine kinase inhibitor selective for EGF, or antisense molecule specific for sequence coding for EGF, or EGF-R.